These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1555 related items for PubMed ID: 19733714

  • 1. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
    Teoh H, Mendelsohn AA, Goodman SG, Jaffer S, Chen RY, Tjia S, Theriault L, Langer A, Leiter LA, Guidelines Based Undertaking for Improvement in Dyslipidemia Related Events (GUIDE) Investigators.
    Am J Cardiol; 2009 Sep 15; 104(6):798-804. PubMed ID: 19733714
    [Abstract] [Full Text] [Related]

  • 2. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X.
    Clin Ther; 2008 Jan 15; 30(1):84-97. PubMed ID: 18343245
    [Abstract] [Full Text] [Related]

  • 3. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
    Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP.
    Curr Med Res Opin; 2007 Sep 15; 23(9):2183-92. PubMed ID: 17692154
    [Abstract] [Full Text] [Related]

  • 4. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
    Roeters van Lennep HW, Liem AH, Dunselman PH, Dallinga-Thie GM, Zwinderman AH, Jukema JW.
    Curr Med Res Opin; 2008 Mar 15; 24(3):685-94. PubMed ID: 18226326
    [Abstract] [Full Text] [Related]

  • 5. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA, Ballantyne CM, Veltri E, Shah A, Bird S, Lin J, Rosenberg E, Tershakovec AM.
    Am J Cardiol; 2009 Feb 01; 103(3):369-74. PubMed ID: 19166691
    [Abstract] [Full Text] [Related]

  • 6. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study.
    Reckless JP, Henry P, Pomykaj T, Lim ST, Massaad R, Vandormael K, Johnson-Levonas AO, Lis K, Brudi P, Allen C.
    Int J Clin Pract; 2008 Apr 01; 62(4):539-54. PubMed ID: 18266852
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
    Sampalis JS, Bissonnette S, Habib R, Boukas S, Ezetrol Add-On Investigators.
    Ann Pharmacother; 2007 Sep 01; 41(9):1345-51. PubMed ID: 17666579
    [Abstract] [Full Text] [Related]

  • 9. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
    Farnier M, Averna M, Missault L, Vaverkova H, Viigimaa M, Massaad R, Vandormael K, Johnson-Levonas AO, Brudi P.
    Int J Clin Pract; 2009 Apr 01; 63(4):547-59. PubMed ID: 19222610
    [Abstract] [Full Text] [Related]

  • 10. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
    Piorkowski M, Fischer S, Stellbaum C, Jaster M, Martus P, Morguet AJ, Schultheiss HP, Rauch U.
    J Am Coll Cardiol; 2007 Mar 13; 49(10):1035-42. PubMed ID: 17349882
    [Abstract] [Full Text] [Related]

  • 11. The impact of ezetimibe and high-dose of statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemia.
    Pitsavos C, Skoumas I, Tousoulis D, Metalinos G, Masoura C, Chrysohoou C, Papadimitriou L, Giotsas N, Toutouza M, Antoniades C, Stefanadis C.
    Int J Cardiol; 2009 May 15; 134(2):280-1. PubMed ID: 18353459
    [Abstract] [Full Text] [Related]

  • 12. Effects of ezetimibe add-on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease.
    Gupta M, Szmitko PE, Tsigoulis M, Braga MF, Kajil M, Herjikaka S, Quan A, Teoh H, Verma S.
    J Cardiovasc Pharmacol; 2010 Sep 15; 56(3):241-5. PubMed ID: 20505518
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).
    Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F, Duffield E, EXPLORER Study Investigators.
    Am J Cardiol; 2007 Mar 01; 99(5):673-80. PubMed ID: 17317370
    [Abstract] [Full Text] [Related]

  • 14. Ezetimibe: a novel option for lowering cholesterol.
    Davidson MH.
    Expert Rev Cardiovasc Ther; 2003 May 01; 1(1):11-21. PubMed ID: 15030293
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia.
    Almutairi F, Peterson TC, Molinari M, Walsh MJ, Alwayn I, Peltekian KM.
    Liver Transpl; 2009 May 01; 15(5):504-8. PubMed ID: 19399742
    [Abstract] [Full Text] [Related]

  • 18. Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia.
    Patel JV, Hughes EA.
    Int J Clin Pract; 2006 Aug 01; 60(8):914-21. PubMed ID: 16893434
    [Abstract] [Full Text] [Related]

  • 19. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.
    Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J.
    Am Heart J; 2005 Mar 01; 149(3):464-73. PubMed ID: 15864235
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
    Stein EA, Ballantyne CM, Windler E, Sirnes PA, Sussekov A, Yigit Z, Seper C, Gimpelewicz CR.
    Am J Cardiol; 2008 Feb 15; 101(4):490-6. PubMed ID: 18312764
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 78.